Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tolvaptan
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Recipient : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oral vasopressin V2-receptor antagonists Samsca® Tablets, Samsca® OD Tablets and SAMSCA® Granules 1% have received regulatory approval in Japan for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secreti...
Product Name : Samsca
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2020
Lead Product(s) : Tolvaptan
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Recipient : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
